

# Bladder Cancer Reference Handout

# Bladder Cancer Dx & Staging

## Urothelial Carcinoma

**Transitional Cell (90% +)**

**Non-Transitional Cell**

### IHC:

CK7+/CK20+

\* Prostate is CK7+/CK20+, PSA+, NKX3.1+

\* RCC is CK7-/CK20-, PAX2+, PAX8+

### Squamous

Adenocarcinoma

Small Cell

Sarcomatoid

Plasmacytoid

Micropapillary

Rhabdoid

## Staging

### T

Ta = non-invasive carcinoma

Tis = carcinoma in situ

T1 = lamina propria, muscularis mucosa

**T2 = muscularis propria = MUSCLE INVASIVE**

T3 = perivesical

T4 = invades local organs

### N

N1 = 1 pelvic LN

N2 = multiple pelvic LN

N3 = common iliac LN

## Stages

IIIA = N1

IIIB = N2-N3

IV = T4b, any N

# Transitional Cell Cancer Tx

**Non-Muscle Invasive Bladder Cancer**  
Ta, Tis, T1 = NMIBC

## TURBT &

Low Risk Adjuvant Tx

High Risk Adjuvant Tx

### Intravesicular Chemotherapy

Gemcitabine, mitomycin, epirubicin  
x1 within 24H of TURBT

### Intravesicular Immunotherapy

BCG Induction +/- Maintenance  
3 weeks post-TURBT → weekly x 6  
1-3Y maintenance

**Muscle Invasive Bladder Cancer**  
T2+ = MIBC

## CYSTECTOMY &

Platinum Eligible: Neo Tx

Platinum Ineligible: Adjuvant Tx

### Gemcitabine/Cisplatin

MVAC = (M) Methotrexate  
(V) Vinblastine  
(A) Adriamycin  
(C) Cisplatin

### Pembrolizumab (PDL1+)

Atezolizumab (PDL1+)

**Metastatic Bladder Cancer**

Platinum Eligible Tx

Platinum Ineligible Tx

Gemcitabine/Cisplatin  
+ maintenance avelumab

### Pembrolizumab (PDL1+)

Atezolizumab (PDL1+)

**2<sup>nd</sup> Line/POD:** Nivolumab, Durvalumab  
Enfortumab  
Erdafitinib (FGFR2/3 mutated)

\* If PDL1-: Gem/Carbo